Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment

Journal of Clinical Densitometry

Volumn 8, Issue 3, 2005, Pages 273-277

  Adachi, Jonathan D ^a,d   Adami, Silvano ^b   Kulkarni, Pandurang M ^c   Wong, Mayme ^c   Stock, John L ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF VERONA   (Italy)

^c ELI LILLY AND COMPANY   (United States)

^d ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Alendronate; Bone mineral density; Least significant change; Raloxifene

Indexed keywords

ALENDRONIC ACID; PLACEBO; RALOXIFENE;

AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 23444445357     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:8:3:273     Document Type: Article

References (21)

1. Lewiecki EM. 2003 Nonresponders to osteoporosis therapy. J Clin Densitom 6:307-314.
2. Bonnick SL. 2002 Current controversies in bone densitometry. Curr Opin Rheumatol 14:416-420.
3. Lenchik L, Kiebzak GM, Blunt BA. 2002 What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 5(suppl):S29-S38.
4. Johnell O, Scheele WH, Lu Y, Reginster J-Y, Need AG, Seeman E. 2002 Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985-992.
5. Sambrook PN, Geusens P, Ribot C, et al. 2004 Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 255:503-511.
6. Luckey M, Kagan R, Greenspan S, et al. 2004 Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 11:405-415.
7. Cummings SR, Karpf DB, Harris F, et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
8. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
9. Watts NB, Cooper C, Lindsay R, et al. 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261.
10. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. 2004 Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. Published on-line 10.1007/s00198-004-1770-7.
11. Kanis JA. 2002 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936.
12. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. 2004 Official positions of the International Society for Clinical Densitometry. South Med J 97:107-110.
13. Miller PD, Bonnick SL. 1999 Clinical Application of Bone Densitometry. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Favus MJ. ed. Philadelphia: Lippincott, Williams & Wilkins, pp. 152-159.
14. Cummings SR, Bates D, Black DM. 2002 Clinical use of bone densitometry: scientific review. JAMA 288:1889-1897.
15. Wasnich RD, Miller PD. 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
16. Hochberg MC, Ross PD, Black D, et al. 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254.
17. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592.
18. Delmas PD, Li Z, Cooper C. 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330-337.
19. Heaney RP. 2003 Is the paradigm shifting? Bone 33:457-465.
20. Patel R, Blake GM, Rymer J, Fogelman I. 2000 Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 11:68-75.
21. Bonnick SL, Johnston CC Jr, Kleerekoper M, et al. 2001 Importance of precision in bone density measurements. J Clin Densitom 4:105-110.